Results 21 to 30 of about 22,047 (159)
Research and Practice in Thrombosis and Haemostasis, 2021 Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa +6 more
doaj +1 more source
Frontiers in Veterinary Science, 2018 Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa +6 more
doaj +1 more source
TH Open, 2018 Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim +7 more
doaj +1 more source
Scientific Reports, 2022 COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama +4 more
doaj +1 more source
BMC Pharmacology and Toxicology, 2019 Background Apixaban effectively lowers the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. Systemic exposure to a given apixaban dose depends on multiple clearance pathways.
Andrea Huppertz +9 more
doaj +1 more source
Arthroscopy Techniques, EarlyView.Abstract Patellar tendon rupture is an uncommon but highly treatable injury, with excellent repair outcomes and low reoperation rates. Chronic patellar tendon ruptures or repair failures pose a clinical challenge, but the success rates of reconstruction with extensor mechanism allograft or autograft are reported to be high in the literature. Still, the
Brett P. Salazar +3 more
wiley +1 more source
Pharmaceutics, 2023 Apixaban and rivaroxaban have first-line use for many patients needing anticoagulation for venous thromboembolism (VTE). The pharmacokinetics of these drugs in non-obese subjects have been extensively studied, and, while changes in pharmacokinetics have ...
Cyril Leven +6 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi +3 more
wiley +1 more source
Clinical Advances in Periodontics, EarlyView.Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira +3 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting.
Kimberley I. Hemelrijk +23 more
wiley +1 more source